Bruce H. Morimoto

发表

Davunetide for progressive supranuclear palsy: Results of the AL-108-231, phase 2/3, 52 week, multi-center, randomized, double-blind, placebo-controlled clinical trial

Andrew J. Lees, Murray Grossman, Anthony E. Lang, 2013 .

QT Interval Prolongation and Drug Development

Bruce H. Morimoto, A. Fox, 2010 .

Evaluating cardiac risk: exposure response analysis in early clinical drug development

Bruce H. Morimoto, S. Paglialunga, J. Grenier, 2018, Drug, healthcare and patient safety.

Revision of the criteria for Alzheimer's disease: A symposium

Ronald C. Petersen, Richard Frank, Michael Gold, 2011, Alzheimer's & Dementia.

Nonclinical Safety Pharmacology

Bruce H. Morimoto, 2018, Early Drug Development.

Safety Pharmacology in Drug Discovery and Development.

Bruce H. Morimoto, A. Fox, E. Castelloe, 2015, Handbook of experimental pharmacology.

Concomitant Medication Use in Progressive Supranuclear Palsy Clinical Trial Participants

Bruce H. Morimoto, M. Gold, C. Gauthier-Campbell, 2016 .

Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial

Clifford R Jack, Murray Grossman, Albert Ludolph, 2014, The Lancet Neurology.

Davunetide: a review of safety and efficacy data with a focus on neurodegenerative diseases

Bruce H. Morimoto, M. Gold, A. Fox, 2013, Expert review of clinical pharmacology.

Drug development of intranasally delivered peptides.

Bruce H. Morimoto, A. Fox, C. Campbell, 2012, Therapeutic delivery.

Therapeutic peptides for CNS indications: Progress and challenges.

Bruce H. Morimoto, 2017, Bioorganic & medicinal chemistry.

Translatability of the S7A core battery respiratory safety pharmacology studies: Preclinical respiratory and related clinical adverse events.

Bruce H. Morimoto, S. Paglialunga, G. Friedrichs, 2019, Journal of pharmacological and toxicological methods.

A Double-Blind, Placebo-Controlled, Ascending-Dose, Randomized Study to Evaluate the Safety, Tolerability and Effects on Cognition of AL-108 after 12 Weeks of Intranasal Administration in Subjects with Mild Cognitive Impairment

Bruce H. Morimoto, A. Blackwell, D. Schmechel, 2013, Dementia and Geriatric Cognitive Disorders.

Intranasal NAP (davunetide) decreases tau hyperphosphorylation and moderately improves behavioral deficits in mice overexpressing α-synuclein

Bruce H. Morimoto, M. Chesselet, I. Gozes, 2014, Pharmacology research & perspectives.

Addressing Alzheimer's disease tangles: from NAP to AL-108.

Bruce H. Morimoto, A. Fox, I. Gozes, 2009, Current Alzheimer research.

A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions

Bruce H. Morimoto, M. Chesselet, F. Mortazavi, 2011, Molecular and Cellular Neuroscience.

NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP).

Bruce H. Morimoto, L. Thal, P. Aisen, 2006, CNS drug reviews.

Update and trends on pharmacokinetic studies in patients with impaired renal function: practical insight into application of the FDA and EMA guidelines

Bruce H. Morimoto, T. Marbury, S. Paglialunga, 2017, Expert review of clinical pharmacology.

Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy

Bruce H. Morimoto, S. Lorenzl, M. Gold, 2012, Neuropsychiatric disease and treatment.

Davunetide Pharmacokinetics and distribution to brain after intravenous or intranasal administration to rat

Bruce H. Morimoto, A. Fox, I. Gozes, 2009 .

Looking for novel ways to treat the hallmarks of Alzheimer's disease

Bruce H. Morimoto, A. Fox, I. Gozes, 2007, Expert opinion on investigational drugs.

A Placebo-Controlled, Parallel Group, Randomized Clinical Trial of AC-1204 in Mild-to-Moderate Alzheimer's Disease.

Bruce H. Morimoto, J. Cummings, M. Farlow, 2020, Journal of Alzheimer's disease : JAD.

Pharmacokinetics in Rat of P8, a Peptide Drug Candidate for the Treatment of Alzheimer’s Disease: Stability and Delivery to the Brain1

Bruce H. Morimoto, L. Hanson, N. Dewji, 2018, Journal of Alzheimer's disease reports.

Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials.

Bruce H. Morimoto, L. Schneider, D. Knopman, 2016, Parkinsonism & related disorders.

Structural studies and cyclization of the neuroprotective octapeptide NAPVSIPQ to improve cell permeability

Bruce H. Morimoto, M. Lipton, Sarah E. St. John, 2020 .

Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations.

Bruce H. Morimoto, J. Jankovic, C. Jack, 2019, Parkinsonism & related disorders.

Tracking the Sugar Rush: Incorporating Continuous Glucose Monitoring Into Multisite Early Clinical Research With Type 2 Diabetes Subjects

Bruce H. Morimoto, S. Paglialunga, C. Fortier, 2018, Clinical pharmacology in drug development.

Drug Development for Neurodegenerative Diseases--Second Annual marcus evans Conference. Advances in drug development for NDD and expediting discovery through novel compounds and sound clinical trials.

Bruce H. Morimoto, 2010, IDrugs : the investigational drugs journal.

Drug Development for Neurodegenerative Diseases--a marcus evans conference. Expediting drugs to the market for neurodegenerative disease indications through novel translational efforts, regulatory clarity, and sound trial design. 7-8 April 2009, Boston, MA, USA.

Bruce H. Morimoto, 2009, IDrugs : the investigational drugs journal.

The repeatable battery for the assessment of neuropsychological status (RBANS) in progressive supranuclear palsy: Baseline data from the Allon Therapeutics AL-108-231 multinational clinical trial

Bruce H. Morimoto, C. Randolph, M. Gold, 2012, Alzheimer's & Dementia.

Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial

Bruce H. Morimoto, C. Jack, L. Schneider, 2014, The Lancet Neurology.